Vasu Dev R, Moses Babu J, Vyas K, Sai Ram P, Ramachandra P, Sekhar N M, Mohan Reddy D N, Srinivasa Rao N
Department of Analytical Research, Discovery Research, Dr. Reddy's Laboratories Ltd., Bollaram Road, Miyapur, Hyderabad 500049, Andhra Pradesh, India.
J Pharm Biomed Anal. 2006 Feb 24;40(3):614-22. doi: 10.1016/j.jpba.2005.10.037. Epub 2005 Dec 5.
During the process development of docetaxel, two polar impurities (Impurities I and II) and two non-polar impurities (Impurities III and IV) were detected by high performance liquid chromatography (HPLC). All the impurities were isolated by Medium Pressure Liquid Chromatography (MPLC). The Impurities I, II, III and IV were identified as 13-[(4S,5R)-2-oxo-4-phenyl-oxazolidine-5-carboxy]-10-deacetyl baccatin III ester, 2'-epi docetaxel, 7-epi docetaxel and 13-[(4S,5R)-2-oxo-4-phenyl-oxazolidine-3,5-dicarboxyl-3-tert-butyl)]-10-deacetyl baccatin III ester, respectively, based on one- (1D) and two-dimensional (2D) nuclear magnetic resonance (NMR) spectroscopy data. The Impurity IV was crystallized and the structure was solved by single crystal X-ray diffraction (XRD). Two impurities (Impurities II and III) were found to be process related, while the remaining two impurities (Impurities I and IV) turned out to be isomers. The formation of these impurities was discussed.
在多西他赛的工艺开发过程中,通过高效液相色谱法(HPLC)检测到两种极性杂质(杂质I和杂质II)和两种非极性杂质(杂质III和杂质IV)。所有杂质均通过中压液相色谱法(MPLC)分离。根据一维(1D)和二维(2D)核磁共振(NMR)光谱数据,杂质I、II、III和IV分别被鉴定为13-[(4S,5R)-2-氧代-4-苯基-恶唑烷-5-羧基]-10-去乙酰浆果赤霉素III酯、2'-表多西他赛、7-表多西他赛和13-[(4S,5R)-2-氧代-4-苯基-恶唑烷-3,5-二羧基-3-叔丁基)]-10-去乙酰浆果赤霉素III酯。杂质IV结晶后,通过单晶X射线衍射(XRD)解析了其结构。发现两种杂质(杂质II和杂质III)与工艺相关,而其余两种杂质(杂质I和杂质IV)是异构体。讨论了这些杂质的形成。